Development of a Novel CAR T-Cell Therapy Targeting Thymic Carcinoma
Proceedings of IMPRS · 30.03.2026 · 8 (1)
DOI: 10.18060/29592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of IMPRS, online erschienen am 30.03.2026. Verfasst von Layla Ahmadi und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Thymic carcinomas are rare anterior mediastinal malignancies with limited treatment options and modest responses to platinum-based chemotherapy. Immune checkpoint inhibitors have shown activity but often cause severe immune-related toxicities. Although CAR T-cell therapy has revolutionized hematologic cancer treatment, its application in thymic carcinoma is limited due to disease rarity, lack of tumor-specific surface antigens, and risks of on-target off-tumor toxicity, especially given the thymus’s role in immune tolerance. Recent studies have identified overexpression of TROP-2, c-KIT, and CD70 in thymic carcinoma, presenting novel therapeutic targets.
Objectives
Profile TROP-2, c-KIT, and CD70 surface expression on thymic carcinoma–relevant cell lines. Engineer CAR constructs targeting each antigen and validate CAR expression on T- cells. Evaluate antigen-specific cytotoxicity of CAR T-Cells in vitro to guide development of multi-antigen CAR T strategies.
Methods
Candidate cell lines were screened for surface expression of TROP-2, c-KIT, and CD70 using quantitative flow cytometry. CAR T-cells were generated from healthy donor PBMCs via lentiviral transduction and expanded ex vivo. Antigen-specific cytotoxicity was evaluated through in vitro coculture assays using selected patient-derived cell lines. Cytotoxic effects were quantified by 7-AAD via flow cytometry.
Results
Flow cytometry confirmed high surface expression of TROP-2 (83%), c-KIT (88%), and CD70 (99%) in T1889, Kasumi, and U266 cell lines, respectively. Lentiviral transduction produced Fab⁺ CAR-T populations of 48.2% (TROP-2), 24.7% (c-KIT), and 47.5% (CD70). All three CAR-T constructs showed antigen-specific cytotoxicity significantly greater than GFP⁺ CD3⁺ controls.
Conclusions
This study provides early in vitro evidence supporting CAR T-cell therapy targeting TROP-2, c- KIT, and CD70 for thymic carcinoma. Results confirm strong CAR expression and potent, selective killing of antigen-positive targets.
Zitieren
APA
Ahmadi, L., Khalifeh, M., Donovski, D., Ceppa, D. P., Loehrer, P., Maniar, R., & Salman, H. (2026). Development of a Novel CAR T-Cell Therapy Targeting Thymic Carcinoma. Proceedings of IMPRS, 8(1). https://doi.org/10.18060/29592
Vancouver
Ahmadi L, Khalifeh M, Donovski D, Ceppa DP, Loehrer P, Maniar R, et al. Development of a Novel CAR T-Cell Therapy Targeting Thymic Carcinoma. Proceedings of IMPRS. 2026;8(1). doi:10.18060/29592
BibTeX
@article{Ahmadi2026,
author = {Ahmadi, Layla and Khalifeh, Malak and Donovski, Dimitar and Ceppa, DuyKhanh Pham and Loehrer, Patrick and Maniar, Rohan and Salman, Huda},
title = {Development of a Novel CAR T-Cell Therapy Targeting Thymic Carcinoma},
journal = {Proceedings of IMPRS},
year = {2026},
volume = {8},
number = {1},
doi = {10.18060/29592}
}
EUVIMED